Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe.

about

Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.

P2860

Q52581473-295E2F22-5232-4519-82EC-2472841FE316

P2860

Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe.

Item

http://www.wikidata.org/entity/Q52670879

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Cost-effectiveness of biologic ...... Crohn's disease across Europe.

@en

Cost-effectiveness of biologic ...... Crohn's disease across Europe.

@nl

type

Item

label

Cost-effectiveness of biologic ...... Crohn's disease across Europe.

@en

Cost-effectiveness of biologic ...... Crohn's disease across Europe.

@nl

prefLabel

Cost-effectiveness of biologic ...... Crohn's disease across Europe.

@en

Cost-effectiveness of biologic ...... Crohn's disease across Europe.

@nl

P1476

Cost-effectiveness of biologic ...... Crohn's disease across Europe.

@en

P2093

Fanni Rencz

http://www.w3.org/2001/XMLSchema#string

Laurent Peyrin-Biroulet

http://www.w3.org/2001/XMLSchema#string

László Gulácsi

http://www.w3.org/2001/XMLSchema#string

Márta Péntek

http://www.w3.org/2001/XMLSchema#string

Petra Baji

http://www.w3.org/2001/XMLSchema#string

Silvio Danese

http://www.w3.org/2001/XMLSchema#string

Stefan Schreiber

http://www.w3.org/2001/XMLSchema#string

Valentin Brodszky

http://www.w3.org/2001/XMLSchema#string

Zsuzsanna Végh

http://www.w3.org/2001/XMLSchema#string

P2860

Infliximab maintenance therapy for fistulizing Crohn's disease

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

Treatment of perianal fistula in Crohn's disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment.

Cost-utility of initial medical management for Crohn's disease perianal fistulae.

Biologics in inflammatory bowel disease: what are the data?

Infliximab for the treatment of fistulas in patients with Crohn's disease.

Vedolizumab as induction and maintenance therapy for Crohn's disease.

Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.

Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease.

Health care resource use and costs in Crohn's disease before and after infliximab therapy.

P304

310-321

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2050640617708952

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Peter Laszlo Lakatos

Peter M Irving

P577

2017-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29511561

http://www.w3.org/2001/XMLSchema#string

P932

5833218

http://www.w3.org/2001/XMLSchema#string

Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe.

about

P2860

P2860

Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932